JGC
AVNR

J. Goldman & Co’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

J. Goldman & Co’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-700,000
Closed -$2.57M – 366
2014
Q1 		$2.57M Sell
700,000
-50,000
-7% -$191K 0.19% 151
2013
Q4 		$2.52M Buy
+750,000
New +$3.1M 0.32% 98

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

J. Goldman & Co's AVNR Position: Q1 2014 in Review

J. Goldman & Co sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2014, closing a stake of 135,000 shares — an estimated $514K sold.

J. Goldman & Co first reported a position in AVNR in Q4 2013 and held it in 1 quarter. The position peaked at $454K in Q4 2013. 100 funds tracked by Wall St. Rank hold AVNR as of Q1 2014.

  • J. Goldman & Co reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2014 after selling out during the quarter.
  • J. Goldman & Co sold 135,000 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2014, an estimated $514K.
  • J. Goldman & Co first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q4 2013 and held it in 1 quarter.
  • J. Goldman & Co's AVANIR PHARMACEUTICALS, INC CL A position peaked at $454K in Q4 2013.
  • 100 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2014.

Based on J. Goldman & Co's 13F filing for Q1 2014, filed 15 May 2014.